Tenegliptin Dosing for Type 2 Diabetes Management

Dosing Considerations for Special Populations

• The Kidney International guideline suggests that, unlike other DPP-4 inhibitors such as alogliptin and sitagliptin, tenegliptin does not require dose reduction in patients with chronic kidney disease, including those on hemodialysis 1

Safety and Concomitant Medication Use

• The Diabetes Care guideline recommends that when tenegliptin is used with insulin or sulfonylureas, consideration should be given to reducing doses of these agents to minimize hypoglycemia risk, following the same principle applied to other DPP-4 inhibitors 2